A treatment for critically ill COVID-19 patients could be on the way, something health officials have been waiting for since the dawn of the pandemic. And if approved, it might be available for hospitalized patients by the fall. The experimental drug sabizabulin — the first to demonstrate a meaningful reduction in deaths among hospitalized COVID-19 cases — has performed so well in clinical trials that independent safety monitors halted the study to fast-track it for approval, according to the drugmaker, Veru, a Miami-based oncology biopharmaceutical company. To read the full story.